NASDAQ:ALNA Allena Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Allena Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.12 -0.01 (-7.46%) (As of 06/24/2022 12:00 AM ET) Add Compare Share Today's Range$0.12▼$0.1450-Day Range$0.08▼$0.2252-Week Range$0.07▼$1.45Volume5.63 million shsAverage Volume7.27 million shsMarket Capitalization$13.36 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allena Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ALNA Stock Forecast (MarketRank)Overall MarketRank™1.73 out of 5 starsMedical Sector874th out of 1,417 stocksBiological Products, Except Diagnostic Industry134th out of 216 stocksAnalyst Opinion: 3.0Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 - 3.0 Analyst's Opinion Consensus RatingAllena Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.00, Allena Pharmaceuticals has a forecasted upside of 5,545.2% from its current price of $0.12.Amount of Analyst CoverageAllena Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 4.4 Community Rank Outperform VotesAllena Pharmaceuticals has received 245 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAllena Pharmaceuticals has received 124 “underperform” votes. (Add your “underperform” vote.)Community SentimentAllena Pharmaceuticals has received 66.40% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Allena Pharmaceuticals and other stocks. Vote “Outperform” if you believe ALNA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALNA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAllena Pharmaceuticals does not currently pay a dividend.Dividend GrowthAllena Pharmaceuticals does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allena Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Allena Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 22.52% of the stock of Allena Pharmaceuticals is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Allena Pharmaceuticals are expected to grow in the coming year, from ($0.32) to ($0.20) per share.Price to Book Value per Share RatioAllena Pharmaceuticals has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Allena Pharmaceuticals (NASDAQ:ALNA)Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.Read More ALNA Stock News HeadlinesJune 1, 2022 | americanbankingnews.comAllena Pharmaceuticals (NASDAQ:ALNA) Upgraded to "Buy" at Zacks Investment ResearchMay 16, 2022 | msn.comShort Volatility Alert: Allena PharmaceuticalsMay 12, 2022 | investorplace.comALNA Stock Alert: 5 Things to Know as Little-Known Allena Pharmaceuticals Soars 100%May 12, 2022 | seekingalpha.comNano cap stock Allena surges on heavy volumeMay 4, 2022 | seekingalpha.comAllena Pharmaceuticals $2.8M direct offeringMay 4, 2022 | finance.yahoo.comAllena Pharmaceuticals Announces $2.8 Million Registered Direct OfferingMarch 22, 2022 | seekingalpha.comAllena downgraded to Neutral at B. Riley citing the end to lead clinical programMarch 21, 2022 | finance.yahoo.comWhy Are Allena Pharma Shares Plunging TodayMarch 21, 2022 | seekingalpha.comAllena extends losses on plans to end trial for lead asset and financial concernsMarch 1, 2022 | finance.yahoo.comAllena Pharmaceuticals, Inc. (ALNA)January 29, 2022 | fool.comAllena Pharmaceuticals, Inc.(ALNA)January 4, 2022 | finance.yahoo.comAllena Stock Is Surging In Premarket Today As It Explores Strategic, Financing AlternativesJanuary 4, 2022 | finance.yahoo.comAllena Pharmaceuticals Provides Clinical and Corporate UpdateSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALNA CUSIPN/A CIK1624658 Webwww.allenapharma.com Phone(617) 467-4577Fax617-916-1871Employees35Year FoundedN/ACompany Calendar Last Earnings5/16/2022Today6/26/2022Next Earnings (Estimated)8/09/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$7.00 High Stock Price Forecast$11.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+2,319.4%Consensus RatingHold Rating Score (0-4)2 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48.66 million Net MarginsN/A Pretax MarginN/A Return on Equity-284.03% Return on Assets-149.54% Debt Debt-to-Equity RatioN/A Current Ratio2.00 Quick Ratio2.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.23 per share Price / Book0.54Miscellaneous Outstanding Shares107,720,000Free Float103,739,000Market Cap$13.36 million OptionableNot Optionable Beta1.98 Allena Pharmaceuticals Frequently Asked Questions Should I buy or sell Allena Pharmaceuticals stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Allena Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALNA, but not buy additional shares or sell existing shares. View analyst ratings for Allena Pharmaceuticals or view top-rated stocks. What is Allena Pharmaceuticals' stock price forecast for 2022? 3 Wall Street research analysts have issued 12 month price targets for Allena Pharmaceuticals' shares. Their ALNA stock forecasts range from $3.00 to $11.00. On average, they anticipate Allena Pharmaceuticals' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 5,545.2% from the stock's current price. View analysts' price targets for Allena Pharmaceuticals or view top-rated stocks among Wall Street analysts. How has Allena Pharmaceuticals' stock performed in 2022? Allena Pharmaceuticals' stock was trading at $0.5925 at the start of the year. Since then, ALNA shares have decreased by 79.1% and is now trading at $0.1240. View the best growth stocks for 2022 here. When is Allena Pharmaceuticals' next earnings date? Allena Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast for Allena Pharmaceuticals. How were Allena Pharmaceuticals' earnings last quarter? Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) posted its quarterly earnings results on Monday, May, 16th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.02. View Allena Pharmaceuticals' earnings history. Who are Allena Pharmaceuticals' key executives? Allena Pharmaceuticals' management team includes the following people: Dr. Alexey L. Margolin Ph.D., Co-Founder & Chairman (Age 69, Pay $70k)Dr. Louis Brenner M.B.A., M.D., Pres, CEO & Director (Age 52, Pay $576.86k)Dr. Richard D. Katz, CFO, Principal Financial Officer & Principal Accounting Officer (Age 58, Pay $400.67k)Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 57)Mr. Geoffrey A. Swire, Sr. VP of Corp. Devel., Acting COO & Interim Principal Operating Officer (Age 49)Mr. Hugh Wight, Sr. VP of Technical OperationsDr. Alicja Januszewicz Ph.D., VP of People & CultureDr. David J. Clark, Chief Medical Officer (Age 57)Mr. Stephen Yu, Sr. VP of Corp. Quality What is Louis Brenner, M.D.'s approval rating as Allena Pharmaceuticals' CEO? 1 employees have rated Allena Pharmaceuticals CEO Louis Brenner, M.D. on Glassdoor.com. Louis Brenner, M.D. has an approval rating of 100% among Allena Pharmaceuticals' employees. This puts Louis Brenner, M.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Allena Pharmaceuticals' key competitors? Some companies that are related to Allena Pharmaceuticals include Protalix BioTherapeutics (PLX), Protalix BioTherapeutics (PLX), Senti Biosciences (SNTI), MiNK Therapeutics (INKT), IN8bio (INAB), PharmaCyte Biotech (PMCB), OKYO Pharma (OKYO), Evaxion Biotech A/S (EVAX), AVROBIO (AVRO), Cognition Therapeutics (CGTX), Pluristem Therapeutics (PSTI), Xtant Medical (XTNT), AIM ImmunoTech (AIM), CASI Pharmaceuticals (CASI) and Entera Bio (ENTX). View all of ALNA's competitors. What other stocks do shareholders of Allena Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allena Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), VYNE Therapeutics (VYNE), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD), VBI Vaccines (VBIV), Acasti Pharma (ACST) and Miragen Therapeutics (MGEN). When did Allena Pharmaceuticals IPO? (ALNA) raised $80 million in an initial public offering on Thursday, November 2nd 2017. The company issued 5,300,000 shares at $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Allena Pharmaceuticals' stock symbol? Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA." Who are Allena Pharmaceuticals' major shareholders? Allena Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (2.88%) and Frazier Management LLC (1.14%). Company insiders that own Allena Pharmaceuticals stock include Edward Wholihan and Louis Md Brenner. View institutional ownership trends for Allena Pharmaceuticals. Which major investors are selling Allena Pharmaceuticals stock? ALNA stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., and Frazier Management LLC. Company insiders that have sold Allena Pharmaceuticals company stock in the last two years include Edward Wholihan, and Louis Md Brenner. View insider buying and selling activity for Allena Pharmaceuticals or view top insider-selling stocks. How do I buy shares of Allena Pharmaceuticals? Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Allena Pharmaceuticals' stock price today? One share of ALNA stock can currently be purchased for approximately $0.12. How much money does Allena Pharmaceuticals make? Allena Pharmaceuticals (NASDAQ:ALNA) has a market capitalization of $13.36 million. How many employees does Allena Pharmaceuticals have? Allena Pharmaceuticals employs 35 workers across the globe. How can I contact Allena Pharmaceuticals? Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The official website for Allena Pharmaceuticals is www.allenapharma.com. The company can be reached via phone at (617) 467-4577, via email at [email protected], or via fax at 617-916-1871. This page (NASDAQ:ALNA) was last updated on 6/26/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here